Clearmind Medicine Inc. has announced additional positive topline safety results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD). The results, which have already been presented, indicate no serious adverse events and strong tolerability, consistent with findings from the first cohort. The multinational, multicenter study is assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The second cohort completed treatment at sites including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651110-en) on February 09, 2026, and is solely responsible for the information contained therein.